Malgaroli, Matteo http://orcid.org/0000-0003-4209-6939
Szuhany, Kristin L.
Riley, Gabriella
Miron, Carly D.
Park, Jae Hyung
Rosenthal, Jane
Chachoua, Abraham
Meyers, Marleen
Simon, Naomi M.
Funding for this research was provided by:
national institutes of health (2KL2TR001446-06A1, 5KL2 TR001446-05, K23MH122773)
american foundation for suicide prevention (PRG-0-104-19)
Article History
Received: 28 July 2021
Accepted: 19 February 2022
First Online: 28 February 2022
Declarations
:
: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. No funding sources played any role in the writing of this manuscript or in the decision to submit the article for publication.
: The questionnaires and methodology for this study was approved by the IRB at NYU Langone Health.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable
: In the past 36 months, Naomi M. Simon reports the following: (1) research grants from the Department of Defense, NIH, PCORI, American Foundation for Suicide Prevention, and Vanda Pharmaceuticals Inc.; (2) speaking/CME/consulting from Bionomics Limited, Praxis Therapeutics, Genomind, BehavR LLC, Engrail Therapeutics Inc., Cerevel, Aptinyx, and Wiley (Deputy Editor Depression and Anxiety); (3) Royalty from Wolters Kluwer (UpToDate) and APA Publishing (Textbook of Anxiety, Trauma and OCD Related Disorders 2020); and (4) equity (spouse) from G1 Therapeutics and Zentalis. Dr. Chachoua reports sitting on the board of Tilray. Matteo Malgaroli, Kristin L. Szuhany, Gabriella Riley, Carly D. Miron, Jae Hyung Park, Jane Rosenthal, and Marleen Meyers have no relevant conflicts of interest to report.